Relapsed/Refractory Diffuse Large B-cell Lymphoma Clinical Trials
25 clinical trials for Relapsed/Refractory Diffuse Large B-cell Lymphoma across international registries, including 6 currently recruiting participants. Compare status, phase, eligibility criteria and locations.
- A Study of APG-3288 in Relapsed/Refractory Blood Cancers — RECRUITING · PHASE1
- A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL — RECRUITING · PHASE3
- Hypofractionation Radiotherapy in Combination With Glofitamab in Relapsed/Refractory Diffuse B-cell Lymphoma With Baseline High Tumor Burden — RECRUITING · PHASE2
- Low Dose Epcoritamab Plus GemOx in R/R DLBCL — RECRUITING · PHASE2
- Safety and Efficacy of Early Second Infusion of Axi-cel Based on ctDNA for R/R Large B - Cell Lymphoma — RECRUITING · PHASE1
- Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma — RECRUITING · PHASE3
- A pivotal Phase II randomised, multi-centre, open-label study to evaluate the efficacy and safety of MB-CART2019.1 compared to standard of care therapy in participants with relapsed/refractory diffuse large B-cell lymphoma (R-R DLBCL), who are not eligible for high-dose chemotherapy and autologous stem cell transplantation — TERMINATED · PHASE2
- Glofitamab in B-NHL Using Mid-Therapy Intratumoral Transcriptomics — NOT_YET_RECRUITING · PHASE2
- A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma — ACTIVE_NOT_RECRUITING · PHASE2
- Efficacy and Safety of Sequential Autologous Hematopoietic Stem Cell Transplantation Combined With Tafasitamab, Lenalidomide, and Standard Immunochemotherapy for Relapsed/Refractory Diffuse Large B-cell Lymphoma — ACTIVE_NOT_RECRUITING · PHASE2
- A multi-center single arm Phase II study to evaluate the safety and efficacy of genetically engineered autologous cells expressing anti-CD20 and anti-CD19 specific chimeric antigen receptor in subjects with relapsed and/or refractory diffuse large B cell lymphoma — OTHER · PHASE2
- A Phase 2/3, Multicenter Randomized Study of Rituximab-Gemcitabine-
Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR DLBCL). — TERMINATED · PHASE3
- Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma — COMPLETED · PHASE3
- Cluster of Differentiation Antigen 19/22(CD19/22) CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma — TERMINATED · PHASE1
- Study of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCL — ACTIVE_NOT_RECRUITING · PHASE2
- Zanubrutinib, in Combination With Lenalidomide, With or Without Rituximab in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma — COMPLETED · PHASE1
- C4971006: A PHASE 1b/2, OPEN-LABEL STUDY OF PF-07901801 IN COMBINATION WITH GLOFITAMAB AFTER A FIXED, SINGLE DOSE OF OBINUTUZUMAB IN PARTICIPANTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA NOT ELIGIBLE FOR STEM CELL TRANSPLANTATION — OTHER · PHASE2
- NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma — TERMINATED · PHASE2
- A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed/Refractory Diffuse Large B-Cell Lymphoma — COMPLETED · PHASE2
- GPL in Patients with Relapsed/refractory Diffuse Large B Cell Lymphoma — ACTIVE_NOT_RECRUITING · PHASE2
- A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Safety and Efficacy of Polatuzumab Vedotin in Combination with Rituximab Plus Gemcitabine Plus Oxaliplatin (R- GEMOX) Versus R- GEMOX Alone in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma — OTHER · PHASE3
- Study of BEBT-908 Combined With Drugs in the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma — OTHER · PHASE1
- Axicabtagene Ciloleucel Expanded Access Study — OTHER
- A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies — COMPLETED · PHASE1
- A Study of ATG-010 in Combination With ATG-008 in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma — TERMINATED · PHASE1
Refine this search